Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355385 | 1.00 | BRD4 (0.37) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL23523775 | 0.89 | GSK3B (0.42) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL30355794 | 0.89 | GSK3B (0.42) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL30355424 | 0.87 | GSK3B (0.33) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL23523727 | 0.87 | GSK3B (0.33) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL23524381 | 0.86 | GSK3B (0.34) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL30355734 | 0.86 | GSK3B (0.34) | BRD4GSK3BEGLN2CDK1PRKCQ | |
| SCHEMBL23524286 | 0.85 | BRD4 (0.39) | BRD4GSK3BCDK1PRKCQMAP3K1 | |
| SCHEMBL30355625 | 0.85 | BRD4 (0.39) | BRD4GSK3BCDK1PRKCQMAP3K1 | |
| SCHEMBL23523920 | 0.83 | KDM1A (0.36) | GSK3BEGLN2NPC1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | BRD4 808/4885GSK3B 2521/4885EGLN2 1849/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | BRD4 1755/4885GSK3B 1281/4885EGLN2 317/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | BRD4 808/4885GSK3B 2521/4885EGLN2 1849/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | BRD4 808/4885GSK3B 2521/4885EGLN2 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.